NUVB News and Press, Nuvation Bio Inc. Class A From 10/03/23

2023-10-03 04:47:57 ET Summary Nuvation Bio is developing BET inhibitors for solid tumors, with lead asset NUV-868 in phase 1/1b trials. BET proteins play a role in gene regulation and chromatin remodeling, and inhibiting them may be therapeutic for cancer. NUV-868 is highly s...

2023-08-24 02:48:55 ET Summary Abrams' 13F portfolio value increased from $3.16B to $3.48B this quarter. The number of holdings in the portfolio increased from 15 to 16. The top three stakes in the portfolio make up approximately 45% of the total. This article is par...

2023-08-03 17:57:20 ET Nuvation Bio press release ( NYSE: NUVB ): Q2 GAAP EPS of -$0.09 beats by $0.02 . As of June 30, 2023, Nuvation Bio had cash, cash equivalents and marketable securities of $630.9 million. For further details see: Nuvation Bio GAAP EPS o...

Enrollment ongoing in the Phase 1b study of NUV-868 in combination with olaparib or enzalutamide Enrollment ongoing in the Phase 1 monotherapy study of NUV-868 Expect to submit an IND for first Drug-Drug Conjugate (DDC) clinical candidate by year end 2023 Announced formati...

Scientific Advisory Board members bring significant global expertise in oncology drug and clinical development Nuvation Bio Inc. (NYSE: NUVB), a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates,...

2023-05-25 01:43:01 ET Summary David Abrams’ 13F portfolio value increased this quarter from $2.80B to $3.16B. The number of positions remained steady at 15. Cantaloupe stake was increased while decreasing Teva Pharmaceutical. The top three positions are Lithia Motors, ...

2023-05-04 17:53:35 ET Nuvation Bio press release ( NYSE: NUVB ): Q1 GAAP EPS of -$0.10. Strong balance sheet with cash, cash equivalents and marketable securities of $646.6 million as of March 31, 2023 For further details see: Nuvation Bio GAAP EPS of -$0.10

Enrollment ongoing in the Phase 1b study of NUV-868 in combination with olaparib or enzalutamide Enrollment ongoing in the Phase 1 monotherapy study of NUV-868 Expect to submit an IND for first Drug-Drug Conjugate (DDC) clinical candidate by year end 2023 Strong balance sh...

2023-03-15 17:09:08 ET Nuvation Bio press release ( NYSE: NUVB ): Q4 GAAP EPS of -$0.10 beats by $0.02 . As of December 31, 2022, Nuvation Bio had cash, cash equivalents and marketable securities of $661.0 million. For further details see: Nuvation Bio GAAP E...

Initiated both dosing regimens of the Phase 1b study of NUV-868 in combination with olaparib or enzalutamide Dosing ongoing for Phase 1 monotherapy study of NUV-868 Nominated undisclosed Drug-Drug Conjugate (DDC) as first clinical candidate; expect to submit an IND by year end 202...